H. Zou

发表

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

J. Christensen, B. Mroczkowski, L. Funk, 2011, Journal of medicinal chemistry.

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

Shinji Yamazaki, J. Christensen, B. Mroczkowski, 2007, Molecular Cancer Therapeutics.

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

Shinji Yamazaki, Gordon Alton, Pei-Pei Kung, 2007, Cancer research.

Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.

Charles D. McDermott, H. Zou, K. Appelt, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

Shibing Deng, Hui Wang, Shinji Yamazaki, 2015, Cancer cell.

Translational Modeling for An Orally Available Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Ros

S. Yamazaki, H. Zou, P. Vicini, 2014 .

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

M. McTigue, Sergei L Timofeevski, Qiuhua Li, 2015, Proceedings of the National Academy of Sciences.

Pharmacodynamic Relationships in Nonclinical Tumor Models: A Case Study of Orally Available Novel Inhibitors of Anaplastic Lymphoma Kinase AUTHORS:

S. Yamazaki, H. Zou, P. Vicini, 2014 .

Pharmacodynamic Relationships in Nonclinical Tumor Models: A Case Study of Orally Available Novel Inhibitors of Anaplastic Lymphoma Kinase AUTHORS:

S. Yamazaki, H. Zou, P. Vicini, 2014 .

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain expos

Wei Liu, Huichun Zhu, Dac Dinh, 2014, Journal of medicinal chemistry.

Abstract A277: PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1G2032R mutant in preclinical tumor models.

Sergei L Timofeevski, S. Yamazaki, Qiuhua Li, 2013 .

Discovery of (10R)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2H-8,4-(Metheno)Pyrazolo[4,3-H][2,5,11]Benzoxadiazacyclotetradecine-3-Carbonitrile (Pf-06463922), a Macrocyclic Inhibitor of Alk/Ros1 with Pre-Clinical Brain Exposure and Broad Spectrum Potency Against Alk-Resistant

Huichun Zhu, Benjamin J. Burke, John Charles Kath, 2014 .

Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of

J. Christensen, J. Cui, M. Tran-Dube, 2012, Journal of medicinal chemistry.

Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials

Charles D. McDermott, H. Zou, S. Bender, 1999, Annals of the New York Academy of Sciences.

Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.

J. Christensen, J. Cui, M. Tran-Dube, 2013, Journal of medicinal chemistry.

A Phase I Pharmacologic Study of Necitumumab (imc-11f8), a Fully Human Igg1 Monoclonal Antibody the Alk/ros1 Inhibitor Pf-06463922 Overcomes Primary Resistance to Crizotinib in Alk-driven Neuroblastoma

H. Zou, Y. Mossé, M. Lemmon, 2022 .

Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor

Shinji Yamazaki, Tod Smeal, J. Christensen, 2012, Molecular Cancer Therapeutics.

Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.

J. Christensen, M. McTigue, K. Ryan, 2009, Biochemistry.

Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340.

H. Zou, K. Appelt, V. Yong, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

The ALK / ROS 1 inhibitor PF-06463922 overcomes primary 1 resistance to crizotinib in ALK-driven neuroblastoma 2 3

H. Zou, Y. Mossé, M. Lemmon, 2015 .

Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.

N. Sach, Hong Shen, M. McTigue, 2014, Journal of medicinal chemistry.

Pharmacokinetic/Pharmacodynamic Modeling of Crizotinib for Anaplastic Lymphoma Kinase Inhibition and Antitumor Efficacy in Human Tumor Xenograft Mouse Models

Paolo Vicini, Shinji Yamazaki, Bill J Smith, 2012, Journal of Pharmacology and Experimental Therapeutics.

JPET #188870 1 TITLE: Pharmacokinetic-Pharmacodynamic Modeling of Crizotinib for Anaplastic Lymphoma Kinase Inhibition and Anti-tumor Efficacy in Human Tumor Xenograft Mouse Models AUTHORS:

J. Christensen, S. Yamazaki, Qiuhua Li, 2011 .

Preclinical Development Sensitivity ofSelectedHumanTumorModels toPF-04217903 , a Novel Selective c-Met Kinase Inhibitor

J. Christensen, J. Cui, M. McTigue, 2012 .

Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Ros Oncogene 1

Paolo Vicini, Hui Wang, Shinji Yamazaki, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Translational Pharmacokinetic-Pharmacodynamic Modeling for An Orally Available Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Ros

S. Yamazaki, H. Zou, P. Vicini, 2014 .

Substrate-specific conformational regulation of the receptor tyrosine kinase VEGFR2 catalytic domain.

H. Zou, S. Grant, J. Solowiej, 2013, ACS chemical biology.

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

P. O'Connor, M. McTigue, S. Yamazaki, 2008, Clinical Cancer Research.

Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects

G. S. Walker, T. R. Johnson, J. Christensen, 2015, Xenobiotica; the fate of foreign compounds in biological systems.

Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations

H. Zou, K. Appelt, D. Shalinsky, 1998, Investigational New Drugs.

Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models

Shinji Yamazaki, Bill J Smith, J. Christensen, 2008, Drug Metabolism and Disposition.

Abstract PR10: Is CNS availability for oncology a no-brainer? Discovery of PF-06463922, a novel small molecule inhibitor of ALK/ROS1 with preclinical brain availability and broad spectrum potency against ALK-resistant mutations.

N. Sach, M. McTigue, H. Zou, 2013 .

Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo.

Sergei L Timofeevski, S. Yamazaki, Qiuhua Li, 2013 .

Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor

J. Christensen, J. Cui, M. McTigue, 2012, Molecular Cancer Therapeutics.

Mechanistic Understanding of Translational Pharmacokinetic-Pharmacodynamic Relationships in Nonclinical Tumor Models: A Case Study of Orally Available Novel Inhibitors of Anaplastic Lymphoma Kinase

S. Yamazaki, H. Zou, P. Vicini, 2015, Drug Metabolism and Disposition.

N. Sach, H. Zou, R. Kania, 2014 .